A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients
Status:
Recruiting
Trial end date:
2022-03-07
Target enrollment:
Participant gender:
Summary
This open label, multicenter study allows JBPOS0101 (investigational product) to be given as
either add-on therapy or monotherapy for patients with refractory infantile spasms. The
design and choice of study population of this Phase 2 clinical study is based on the need to
provide initial safety, tolerability, pharmacokinetics (PK), and efficacy outcomes of the
investigational product for future clinical studies.